FZMD (Fuse Medical) Return-on-Tangible-Equity: Negative Tangible Equity% (As of Jun. 2023)


FZMD Fuse Medical Inc FZMD
12 GF Score
Price $0.02
View Full Analysis

What is Fuse Medical Return-on-Tangible-Equity?

Fuse Medical FZMD 12 Return-on-Tangible-Equity is Negative Tangible Equity% as of Jun. 2023. GuruFocus rates FZMD with a GF Score™ of 12/100.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Fuse Medical's annualized net income for the quarter that ended in Jun. 2023 was $1.23 Mil. Fuse Medical's average shareholder tangible equity for the quarter that ended in Jun. 2023 was $-3.50 Mil. Therefore, Fuse Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 was Negative Tangible Equity%.

The historical rank and industry rank for Fuse Medical's Return-on-Tangible-Equity or its related term are showing as below:

FZMD's Return-on-Tangible-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.07
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Fuse Medical  (OTCPK:FZMD) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Fuse Medical Return-on-Tangible-Equity Related Terms


Fuse Medical Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Fuse Medical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fuse Medical Return-on-Tangible-Equity Chart

Fuse Medical Annual Data
Trend Aug13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Tangible Equity 0.00 0.00 0.00 Negative Tangible Equity

Fuse Medical Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 Negative Tangible Equity 0.00 Negative Tangible Equity

FZMD vs GTHP, SONX, PBIO: Return-on-Tangible-Equity Comparison

For the Medical Devices subindustry, Fuse Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fuse Medical Return-on-Tangible-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Fuse Medical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Fuse Medical's Return-on-Tangible-Equity falls into.


FZMD
12GF Score
Fuse Medical Inc FZMD
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fuse Medical Return-on-Tangible-Equity Calculation

Fuse Medical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=3.098/( (-6.722+-3.475 )/ 2 )
=3.098/-5.0985
=Negative Tangible Equity %

Fuse Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2023 )  (Q: Mar. 2023 )(Q: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Mar. 2023 )(Q: Jun. 2023 )
=1.232/( (-3.67+-3.33)/ 2 )
=1.232/-3.5
=Negative Tangible Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of Negative Tangible Equity% mean?
Fuse Medical (FZMD) has a Return-on-Tangible-Equity of Negative Tangible Equity% as of Jun. 2023. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Fuse Medical and its competitors.
Is Fuse Medical's Return-on-Tangible-Equity too high?
Fuse Medical's current Return-on-Tangible-Equity is Negative Tangible Equity%. Overall, Fuse Medical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Fuse Medical's Return-on-Tangible-Equity compare to GTHP and SONX?
Fuse Medical's Return-on-Tangible-Equity of Negative Tangible Equity% can be compared against companies in the Medical Devices & Instruments industry. The industry median Return-on-Tangible-Equity is 4.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.07, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Fuse Medical and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fuse Medical's current Return-on-Tangible-Equity is Negative Tangible Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fuse Medical stock overvalued right now?
Fuse Medical (FZMD) has a current Return-on-Tangible-Equity of Negative Tangible Equity%. The current Return-on-Tangible-Equity is Negative Tangible Equity%. Fuse Medical's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Fuse Medical (FZMD), the current Return-on-Tangible-Equity is Negative Tangible Equity% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Fuse Medical Business Description

Address 4343 Sigma Road, Suite 500, Farmers Branch, TX, USA, 75244
Fuse Medical Inc is a manufacturer, distributor, and wholesaler of medical device implants, offering portfolio of orthopedic implants and biologics including: internal fixation products, upper and lower extremity plating and total joint reconstruction implants, soft tissue fixation and augmentation for sports medicine procedures, spinal implants for trauma, degenerative disc disease and deformity indications, and osteo-biologics, regenerative and connective tissues, which include human allografts, substitute bone materials, tendons, and regenerative tissues. Its portfolio of Orthopedic Implants and Biologics provide products to assist surgeons with positive patient outcomes and cost-effective solutions for its customers including hospitals, medical facilities, and sub-distributors.
12GF Score

Get the complete analysis for FZMD

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price